Document is current
Any future updates will be listed below
-
Authors
Péréon, Yann
Adams, David
Camdessanché, Jean-Philippe
Chanson, Jean-Baptiste
Cintas, Pascal
Magy, Laurent
Signaté, Aïssatou
Solé, Guilhem
Svahn, Juliette
Tard, Céline
Hababou, Cyrla
Attarian, Shahram
-
Funding
Funding for this research was provided by:
alnylam (alnylam)
- License Information
-
More Information
Article History
Received: 25 March 2024
Accepted: 31 January 2025
First Online: 1 March 2025
Declarations
:
: Not applicable.
: Not applicable.
: DA has received consulting fees from Alnylam and Astra Zeneca. DA has received support for attending meetings and travel from Alnylam. SA has received consulting fees from Alnylam, Pfizer and Astra Zeneca. SA has received honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Alnylam, Pfizer and Astra Zeneca. SA has received support for attending meetings from Alnylam and Pfizer. JBC has received support for attending meetings from Alnylam, CSL Behring, LFB and Pfizer. JBC has participated on a Data Safety Monitoring Board or Advisory Board for Alnylam. PC has received consulting fees from Alnylam. PC has received honoraria for presentations from Alnylam. LM has received consulting fees from Alnylam, Pfizer and LFB. LM received support for attending meetings and/or travel from CSL Behring and Novartis. GS has received grants or contracts from Alnylam and Pfizer (study funding paid to his institution). GS has received honoraria for lectures from Alnylam. GS has received honoraria from Alnylam for participation to board. JS has received honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Pfizer. JS has participated on a Data Safety Monitoring Board or Advisory Board for Alnylam. CT has received consulting fees from Alnylam and Pfizer. CT has received honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Alnylam and Pfizer. CT has received support for attending meetings and/or travel from Alnylam and Pfizer. CT has participated on a Data Safety Monitoring Board or Advisory Board for Alnylam and Pfizer. CH is an employee of Alnylam. YP has received consulting fees from Alnylam. YP has received honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events. YP has received support for attending meetings and/or travel from Alnylam. YP has participated on a Data Safety Monitoring Board or Advisory Board for Alnylam. JPC and AS declare no conflicts of interest.
